Schott Pharma Stock - analyst views and long-term positioning

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:51 CET. Details in the imprint.

Schott Pharma (DE000A3ENQ51) continues to attract attention from healthcare-focused investors on the German market. With no new ad-hoc announcements or major analyst rating changes reported today, the spotlight falls on the company’s existing consensus, SDAX role, and long-term business model.

What analysts and the market say

Schott Pharma AG & Co. KGaA returned to the public market in 2023 and is currently traded in the SDAX, making it part of the smaller-cap German equity universe in healthcare-related equipment.

According to current data from German market portals, the stock is covered by several broker houses, with a mixed but generally constructive view on the long-term growth case.

Long-term positioning and moat

The long-term investment narrative centers on injectable drugs and complex biologics, for which Schott Pharma supplies high-value primary packaging and drug delivery components.

Management has repeatedly emphasized in public presentations that structural growth in biologics, vaccines, and specialty medicines supports demand for high-quality containment solutions over many years, independent of short-term macro volatility.

How the company makes money

Schott Pharma generates most of its revenue by developing and manufacturing glass and polymer primary packaging systems for injectable drugs, including prefillable syringes, vials, and cartridges used by pharmaceutical and biotech companies worldwide.

Where the stock trades today

The shares of Schott Pharma (DE000A3ENQ51) trade on Xetra in Frankfurt; the latest available quote from German market data shows the stock changing hands in euros during regular CET trading hours.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.